April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Macular Development in Advanced Posterior Retinopathy of Prematurity
Author Affiliations & Notes
  • Hemang K. Pandya
    Ophthalmology, Kresge Eye Institute, Canton, Michigan
  • Lisa J. Faia
    Associated Retinal Consultants, Royal Oak, Michigan
  • Kimberly A. Drenser
    William Beaumont Hosp,
    Associated Retinal Consultants, Royal Oak, Michigan
  • Footnotes
    Commercial Relationships  Hemang K. Pandya, None; Lisa J. Faia, None; Kimberly A. Drenser, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3148. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hemang K. Pandya, Lisa J. Faia, Kimberly A. Drenser; Macular Development in Advanced Posterior Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3148.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Aggressive Posterior Retinopathy of Prematurity (AP-ROP) is a vitreoretinal abnormality affecting premature babies with extremely low birth weights. This study reports anatomic outcomes after early and complete laser photocoagulation of the entire avascular retina, including areas in close proximity to the fovea, in patients with AP-ROP. We propose novel mechanisms for macular development and ocular maturation and growth that contribute to our understanding of AP-ROP treatment.


Retrospective review of 6 eyes of 3 AP-ROP patients that underwent laser photocoagulation of the entire avascular retina. Serial photographic fundoscopic imaging was performed using RetCam® (MLI Inc., Pleasanton, CA) to compare retinal anatomy before and after treatment.


Mean birth weight and gestational age were 704.8g (range 525-829.3g) and 24.33 weeks (range 23.57-25.57 weeks), respectively. There were 2 female and 1 male patient. The average time to laser was 9.3 weeks after birth, with the mean postmenstrual age of 34 weeks (range 32-36 weeks). Two eyes had zone 1 and 4 eyes had posterior zone 2 disease. Four eyes required additional therapies due to persistent disease: 2 eyes required intravitreal bevacizumab (Avastin, Genentech, Inc., San Francisco, CA) followed by additional laser and 2 eyes required two separate treatments of pegaptanib (Macugen, OSI Pharmaceuticals, Inc., Long Island, NY). Three eyes went on to develop 4A detachments, which were successfully treated. Mean follow-up was 7 months (range 3-12 months). All 6 eyes experienced transverse growth, with expansion of the posterior pole and anterior displacement of the previous laser treatment.


Confluent photocoagulation of the entire avascular retina, regardless of foveal proximity, should be the mainstay for treating AP-ROP. Subsequent photocoagulation should be conducted within 10 days to areas previously hidden by neovascularization to ensure prudent therapy. Macular development may involve retinal stretching and/or AP retinal growth through yet to be established mechanisms  

Keywords: retinopathy of prematurity • retinal development • visual development: infancy and childhood 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.